On November 4, 2022 Flatiron Health reported their attendance and presence at the ISPOR, The Professional Society for Health Economics and Outcomes Research Europe 2022 Conference, held in Vienna, Austria this year (Press release, Flatiron Health, NOV 4, 2022, View Source [SID1234623143]). A total of 7 presentations will be presented by Flatiron, including one oral podium presentation and one in-person poster being recognized as top 5% finalists for 2022 Research Presentation Awards. Research presented at this year’s ISPOR Europe represents an important milestone in Flatiron Health’s growth and leadership within real-world evidence and clinical research, as learnings from the experiences of every person with cancer in the US begin to inform and improve the lives of people living with cancer in many other parts of the world.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The quality of our research being presented at this year’s ISPOR Europe demonstrates our commitment to use data for good," said Javier Jimenez, Flatiron Chief Medical Officer. "Flatiron is dedicated to thoughtful and rigorous generation of EHR-derived real-world evidence, and innovating machine learning technologies to learn from every person with cancer."

Highlights include:

an oral podium presentation using machine learning to accelerate outcomes research, replicating and comparing results to health outcomes studies using a traditional abstraction approach.
a poster on real-world radiology imaging data with an assessment of the representativeness of scan-derived cohorts relative to a broader population of patients living with advanced non-small cell lung cancer and DLBCL.
a poster presentation replicating comparative-effectiveness findings with machine learning extracted variables as an alternative to expert-abstracted data in patients with metastatic non-small cell lung cancer.
a workshop featuring Flatiron Health researcher, Corey Benedum, discussing the use of real-world data at scale, specifically focusing on how machine learning extraction of information from unstructured documents can enable learnings from all patients.

On November 4, 2022 Peak Bio, Inc. ("Peak Bio" or the "Company") (NASDAQ: PKBO), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, reported that it has entered into a Common Stock Purchase Agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital") (Press release, Peak Bio, NOV 4, 2022, View Source [SID1234623142]). The Agreement governs a committed equity facility that provides the Company with the right, without the obligation, to sell White Lion Capital up to $100 million of its common stock over a 36-month period, subject to certain limitations and conditions. The Company intends to use the net proceeds from the transaction for working capital to support its clinical and preclinical programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stephen LaMond, PharmD, MBA, Peak Bio, Inc. COO, commented, "We are pleased to announce the closing of the Agreement with White Lion Capital as it demonstrates the strong vote of confidence we are receiving from investors. This equity line will help bolster our investments in our programs and allow for opportunistic portfolio expansion. "

On November 4, 2022 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that the following presentations will be presented at the 64th ASH (Free ASH Whitepaper) (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana (Press release, Innate Pharma, NOV 4, 2022, View Source [SID1234623141]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lacutamab in patients with advanced Sezary syndrome: results from an interim analysis of the TELLOMAK phase 2 trial
Abstract Number: 1631
Session Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
Session Date and Time: Saturday, December 10, 2022, 5:30 PM – 7:30 PM
Location: Ernest N. Morial Convention Center, Hall D
Presenter: Dr Pierluigi Porcu, Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Thomas Jefferson University Hospitals, Philadelphia
Scientific Symposia: Antibody-Based NK Cell Engager Therapeutics
Session Title: Biology and Translation of NK Cells
Session date and Time: Saturday December 10th, 2022, 2:00 PM – 3:15 PM
Location: Ernest N. Morial Convention Center, 293-294
Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma
An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS) (Sanofi)
Abstract Number: 3329
Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Session Date and Time: Sunday, December 11, 2022, 6:00 PM – 8:00 PM
Location: Ernest N. Morial Convention Center, Hall D
Presenter: Anthony Stein, MD
The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement (Sanofi)
Abstract Number: 4486
Session Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
Session Date and Time: Monday, December 12, 2022, 6:00 PM – 8:00 PM
Location: Ernest N. Morial Convention Center, Hall D
Presenter: Alexandre Tang, Ph.D
The posters and presentation will be available on the Publications section of innate-pharma.com following the meeting.

About Lacutamab:

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

Lacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.

About ANKETTM:

ANKETTM (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.

This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.

Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule.

On November 4, 2022 Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), reported that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting which will be held November 8 – 12, 2022 at the Boston Convention and Exhibition Center in Boston, MA (Press release, Molecular Templates, NOV 4, 2022, View Source [SID1234623140]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day event will include in-person presentations by the senior leadership team of Molecular Templates reviewing the technology of next-generation ETBs, the clinical highlights informing development strategies, and the data presented at SITC (Free SITC Whitepaper) around its PD-L1 targeting MT-6402 and CTLA-4 targeting MT-8421 programs. The event will be webcasted and take place 11:30am – 12:30pm ET Friday, November 11, 2022, at the Boston Convention Center during SITC (Free SITC Whitepaper)’s 37th Annual Meeting. A live Q&A session will follow the presentation.

Four abstracts to be presented at SITC (Free SITC Whitepaper) include:
"We look forward to updating the community on data presented at SITC (Free SITC Whitepaper). We believe the approach MTEM has taken in immuno-oncology is highly differentiated and that we are seeing early signs this approach can provide patient benefit and open up new avenues for targeting PD-L1 and CTLA-4," said Eric Poma, Chief Executive Officer of Molecular Templates.

On November 4, 2022 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported it will host a conference call and webcast on Tuesday, November 15, 2022 at 5:00 p.m. (EST) to discuss corporate developments and financial results for the third quarter ended September 30, 2022 (Press release, Navidea Biopharmaceuticals, NOV 4, 2022, View Source [SID1234623139]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress. Management will be available to answer questions live immediately following the earnings announcement and prepared remarks portion of the call.

View Source

A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.